It's time to switch patients' prescriptions to the FreeStyle Libre 2 system

Abbott‘s original FreeStyle Libre sensors will be discontinued in Ireland at the end of September 2024.
Find out what you need to do >

ADC-95357 v1.0 06/24

Ireland (IE)

Real-World Data

Analysing the impact of the FreeStyle Libre Portfolio on the lives of real users

A man with a FreeStyle Libre 2 sensor on his arm talking to a healthcare professional and showing him his phone

Outcomes for people with diabetes

The FreeStyle Libre Portfolio is making a real impact on outcomes for people with diabetes.

Reduced hypoglycaemia1,2

Decreased HbA1c3

Increased time in range4

Improved quality of life6

Learn more about the FreeStyle Libre Portfolio in our Educational Modules

Access the modules

Reduced hypoglycaemia

The FreeStyle Libre systems* are clinically proven to significantly reduce  hypoglycaemia in T1D1 and T2D2 patients

Impact Study1: T1D Patients

Hypoglycaemia is defined as <3.9 mmol/L.

Study data collected with the FreeStyle Libre system and is applicable to the FreeStyle Libre 2 system based on technological similarities.

Replace Study2: T2D Patients

Study data collected with the FreeStyle Libre system and is applicable to the FreeStyle Libre 2 system based on technological similarities.

Decreased HbA1c

The FreeStyle Libre systems* significantly reduce HbA1c for adults with diabetes in the UK

The ABCD Nationwide Audit3 explored the real-world experiences of FreeStyle Libre users in the UK and the impact on glycaemic control.

3,182

adults

with T1D or T2D
with 7.5 months followup

5.2

mmol/mol

average reduction in HbA1c

From baseline 67.5 mmol/mol HbA1c across the entire study population

12.3

mmol/mol

average reduction in HbA1c
for FreeStyle Libre users with a starting baseline of >69.5mmol/mol

Increased time in range

FreeStyle LibreLink app users experience better glycaemic control and more time in range4

1.2 hours

more time in range4


FreeStyle LibreLink◊ users spent 5% (1.2 hours) more Time In Range vs Reader users,4 which is clinically significant.5

Real-world evidence comparing app vs reader (65.3% vs 60.5%, time in 3.9-10.0 mmol/L range, respectively) Real-world evidence comparing app vs reader (65.3% vs 60.5%, time in 3.9-10.0 mmol/L range, respectively)

Improved quality of life

Use of the FreeStyle Libre systems* is associated with improved quality of life in T1D and T2D6

66%

reduction in hospital admissions
in T1D and T2D6

from 13.7% to 4.7% at 12 months

A RWE study of the effect of the FreeStyle Libre 2 system on 1365 T1D and T2D patients on insulin over 1 year: endpoints included A1c, hypoglycaemia, and patient-reported outcomes.

(p=0.005)

33%

reduction in DKA
or hypo admissions
in T1D7

from 3.3% to 2.2% at 12 months

A RWE study of the effect of the FreeStyle Libre 2 system on 1913 T1D patients at 6 months and 1 year: endpoints included quality of life, number of hospital admissions, and hypoglycaemia.

(p=0.0031)

58%

reduction in work absenteeism
in T1D and T2D6

from 18.5% to 7.7% at 12 months

Real world data showed that work absenteeism in patients <65 years was decreased by 60% in patients using a FreeStyle Libre system (from 20.4% to 8.3%; p<0.001).

A RWE study of the effect of the FreeStyle Libre system on 1365 T1D and T2D patients on insulin over 1 year: endpoints included A1c, hypoglycaemia, and patient-reported outcomes.

(p=0.001)

Get started today

Learn more about the FreeStyle Libre Portfolio and its benefits for your patients with our FreeStyle Academy

Register for FreeStyle Academy

Clinical Evidence

Clinical benefits for a broad range of T1D and T2D patients.
 

EXPLORE CLINICAL EVIDENCE

Training Resources

Explore our training resources to help you to help your patients understand Time in Range better.
 

EXPLORE TRAINING RESOURCES

Educational Modules

Learn more about Time in Range and the FreeStyle Libre system through our Healthcare Professional education modules.

START LEARNING

 

Webinars

We offer various on-demand webinars for Healthcare Professionals including Understanding Time in Range.

EXPLORE WEBINARS

 

Webcast Series

Learn more about Time in Range in our CME accredited three-module webcast series.

START THE SERIES

References & Disclaimers

Images are for illustrative purposes only. Not real patient, data or healthcare professional.

* FreeStyle Libre systems refers to the FreeStyle Libre and FreeStyle Libre 2 systems.

◊ The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink may require registration with LibreView. 

1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.

2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1): 55-73.

3. Deshmukh H, et al. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care 2020;43:2153–2160.

4. Kao K., Journal of Diabetes Science and Technology. (2021): https://doi.org/10.1177%2F19322968211044141.

5. Battelino T., Diabetes Care. (2019): https://doi.org/10.2337/dci19-0028

6. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.

7. Charleer, S. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610.

 

Why The FreeStyle Libre Systems?
FreeStyle Portfolio
Scientific Resources & Education
FreeStyle Portal
Help & Support
Abbott

The sensor housing, FreeStyle Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorisation of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of Ireland. The product images are for illustrative purposes only.

©️ 2024 Abbott Laboratories Limited. All rights reserved.

Registered Number: 11542. Registered Office: Block B, Liffey Valley Office Campus, Quarryvale, Dublin 22 D22 X0Y3, Ireland.

Do you want to leave this page?

The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.

Do you want to leave this page?

This website is only for healthcare professionals who live and practice in Ireland.

If you're a healthcare professional located in a different country, please select your country's website from the list of our global sites or contact your local Abbott representative for correct information about the products available in your country.

If you're not a healthcare profressional, click here to go to the FreeStyle Libre consumer website for Ireland.